Literature DB >> 23098635

Pharmacokinetics of hydrocodone and hydromorphone after oral hydrocodone in healthy Greyhound dogs.

Butch KuKanich1, Julia Spade.   

Abstract

The purpose of this study was to determine the pharmacokinetics of hydrocodone and its active metabolite hydromorphone in six healthy Greyhound dogs. Hydrocodone bitartrate was administered at a targeted dose of 0.5 mg/kg PO. Plasma concentrations of hydrocodone and hydromorphone were determined by liquid chromatography triple quadrupole mass spectrometry. The mean hydrocodone CMAX was 11.73 ng/mL at 0.74 h with a terminal half-life of 1.60 h. The mean hydromorphone CMAX was 5.2 ng/mL at 1.37 h with a terminal half-life of 3.07 h. Mean plasma hydromorphone concentrations exceeded 2 ng/mL from 0.5 to 8 h after hydrocodone administration. Further studies assessing the antinociceptive effects of oral hydrocodone are needed.
Copyright © 2012 Elsevier Ltd. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 23098635      PMCID: PMC4219551          DOI: 10.1016/j.tvjl.2012.09.008

Source DB:  PubMed          Journal:  Vet J        ISSN: 1090-0233            Impact factor:   2.688


  7 in total

1.  Pharmacokinetics and physiological effects of intravenous hydromorphone in conscious dogs.

Authors:  A G P Guedes; M G Papich; E P Rude; M A Rider
Journal:  J Vet Pharmacol Ther       Date:  2008-08       Impact factor: 1.786

2.  The effects of inhibiting cytochrome P450 3A, p-glycoprotein, and gastric acid secretion on the oral bioavailability of methadone in dogs.

Authors:  B Kukanich; B D X Lascelles; A M Aman; K L Mealey; M G Papich
Journal:  J Vet Pharmacol Ther       Date:  2005-10       Impact factor: 1.786

3.  Radioimmunoassay determination of the absolute oral bioavailabilities and O-demethylation of codeine and hydrocodone in the dog.

Authors:  J W Findlay; E C Jones; R M Welch
Journal:  Drug Metab Dispos       Date:  1979 Sep-Oct       Impact factor: 3.922

4.  Determination of oxycodone in plasma and identification of a major metabolite.

Authors:  S H Weinstein; J C Gaylord
Journal:  J Pharm Sci       Date:  1979-04       Impact factor: 3.534

5.  Effect of cytochrome P450 2D1 inhibition on hydrocodone metabolism and its behavioral consequences in rats.

Authors:  D M Tomkins; S V Otton; N Joharchi; N Y Li; R F Balster; R F Tyndale; E M Sellers
Journal:  J Pharmacol Exp Ther       Date:  1997-03       Impact factor: 4.030

6.  Pharmacokinetics of morphine and plasma concentrations of morphine-6-glucuronide following morphine administration to dogs.

Authors:  B KuKanich; B D X Lascelles; M G Papich
Journal:  J Vet Pharmacol Ther       Date:  2005-08       Impact factor: 1.786

7.  Development of a canine nociceptive thermal escape model.

Authors:  Kirsten Wegner; Kjersti A Horais; Nicolle A Tozier; Michael L Rathbun; Yuri Shtaerman; Tony L Yaksh
Journal:  J Neurosci Methods       Date:  2007-09-29       Impact factor: 2.390

  7 in total
  1 in total

1.  Effectiveness of tapentadol hydrochloride for treatment of orthopedic pain in dogs: A pilot study.

Authors:  Nina R Kieves; James Howard; Phillip Lerche; Jeffrey Lakritz; Turi K Aarnes
Journal:  Can Vet J       Date:  2020-03       Impact factor: 1.008

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.